Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

Aug 30, 2024

SELL
$40.01 - $73.97 $20,405 - $37,724
-510 Closed
0 $0
Q4 2019

Aug 30, 2024

BUY
$37.13 - $74.62 $11,139 - $22,386
300 Added 142.86%
510 $36.5 Million
Q1 2019

Aug 30, 2024

BUY
$27.39 - $68.41 $5,751 - $14,366
210 New
210 $12.5 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.